Tumor angiogenesis in 75 cases of pleomorphic carcinoma of the lung

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3331-3337

  Tsubata, Yukari ^a   Sutani, Akihisa ^a   Okimoto, Tamio ^a   Matsuura, Motoki ^b   Murakami, Isao ^c   Usuda, Ryousuke ^d   Okumichi, Tsuneo ^e   Kakegawa, Sei Ichi ^f   Togashi, Kenichi ^g   Kosaka, Shinji ^h   Yamashita, Yoshinori ⁱ   Kishimoto, Koji ^a   Kuraki, Takashige ^a   Isobe, Takeshi ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c Saijo cho   (Japan)

^d SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^e Yoshijima Hospital   (Japan)

^f National Hospital Organization   (Japan)

^g NAGAOKA RED CROSS HOSPITAL   (Japan)

^h SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁱ Chugoku Cancer Center   (Japan)

Author keywords

Angiogenesis; Hypoxia inducible factor 1 ; Immunohistochemistry; Pleomorphic carcinoma; Vascular endothelial cell growth factor

Indexed keywords

CD31 ANTIGEN; CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LUNG PLEOMORPHIC CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL ANALYSIS;

EID: 84865687519     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fishback NF, Travis WD, Moran CA, Guinee DG Jr., McCarthy WF and Koss MN: Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 73: 2936-2945, 1994.
2. Travis WD, Tlavis LB and Devesa SS: Lung cancer. Cancer 75: 191-202, 1995.
3. Mochizuki T, Ishii G, Nagai K, Yoshida J, Mizuno T, Yokose T, Suzuki K and Ochiai A: Pleomorphic carcinoma of the lung. Clinicopathologic characteristics of 70 cases. Am J Surg Pathol 32: 1727-1735, 2008.
4. Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumors. Eur Respir J 18: 1059-1068, 2001.
5. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
6. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T and Tominaga T: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77: 1101-1106, 1996.
7. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF and Ramakrishnan S: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106, 1997.
8. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR and Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541-546, 1997.
9. Eisma RJ, Spiro JD and Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513-517, 1997.
10. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M and Fukui M: Expression of vascular endothelial growth factor and its possible relation with neo-vascularization in human brain tumors. Cancer Res 55: 1189-1193, 1995.
11. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima H, Isobe H, Inoue K and Kawakami Y: Tumor angiogenesis in human lung adenocarcinoma. Cancer 74: 2245-2250, 1994.
12. Yano T, Tanikawa S, Fujie T, Masutani M and Horie T: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 36: 601-609, 2000.
13. Senger DR, Perruzzi CA and Feder J: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629-5632, 1986.
14. Sagisaka S, Uehara M, Harada M, Sato J, Uchiyama H, Imokawa S, Yasuda K, Tanioka F, Suda T and Chida K: Clinicopathological investigation of 5 autopsy cases of pulmonary pleomorphic carcinoma. Jpn J Lung Cancer 50: 803-808, 2010.
15. Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H and Nishimura M, Hokkaido Lung Cancer Clinical Study Group: Clinical characteristic of pleomorphic carcinoma of the lung. Lung Cancer 68: 204-210, 2010.
16. Ramalingam S and Belani CP: Cycoloxygenase-2 inhibitors in lung cancer. Clin Lung Cancer 5: 245-253, 2004.
17. Harris AL: Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 1: 38-47, 2002.
18. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
19. UICC: TNM classification of malignant tumours. 6th and 7th eds. Geneva: UICC, 2002 and 2009.
20. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484, 1996.
21. Rossi G, Cavazza A, Sturm N, Migaldi M, Facciolongo N, Longo L, Mariorana A and Brambilla E: Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements. A clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 27: 311-324, 2003.
22. Isobe T, Herbst RS and Onn A: Current management of advanced non-small cell lung cancer: Targeted therapy. Semin Oncol 32: 315-328, 2005.
23. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C and Sculier JP: The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87: 694-701, 2002.
24. Macchiarini P, Fontanini G, Hardin MJ, Squartini F and Angeletti CA: Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 340: 145-146, 1992.
25. Achiwa H, Yatabe Y, Hida Y, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T and Takahashi T: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinoma. Clin Cancer Res 5: 1001-1005, 1999.
26. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK and Xu XC: Cycoloxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7: 861-867, 2001.
27. Zhu YM, Azahri NS, Yu DC and Woll PJ: Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. BMC Cancer 31: 218-228, 2008.
28. Kim HS, Youm HR, Lee JS, Min KW, Chung JH and Park CS: Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 42: 163-170, 2003.
29. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 85: 881-890, 2001.
30. Yohena T, Yoshino I, Takenaka T, Kameyama T, Ohba T, Kuniyoshi Y and Maehara Y: Upregulation of hypoxia-inducible factor 1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol 4: 284-290, 2009.
31. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
32. Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS and Herbst RS: Treatment with HIF-1α antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 5: 940-949, 2010.
33. Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedlamd DM, Stoller RG, Potter DM, Ivy SP and Belani CP: A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 14: 3456-3461, 2008.
34. Provencio M, Sanchez A, Garrido P, and Valcarcel F: New molecular-targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 1: 91-97, 2010.
35. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G and Erlichman C: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23: 1078-1087, 2005.